Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.11.29 - hypoxia-inducible factor-proline dioxygenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Kidney Injury
Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis associated with Acute Kidney Injury.
Adenocarcinoma
Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand.
Adenocarcinoma of Lung
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma.
Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Adenoma, Oxyphilic
Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated ELGN2-mediated oxygen-sensing response.
Altitude Sickness
EPAS1 and EGLN1 associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau.
Population History and Altitude-Related Adaptation in the Sherpa.
Variants of the low oxygen sensors EGLN1 and HIF-1AN associated with acute mountain sickness.
Anemia
A mechanistic link between renal ischemia and fibrosis.
A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
American chemical society - 239th national meeting - investigating new therapeutic candidates: part 2.
Anemia in conventional hemodialysis: Finding the optimal treatment balance.
Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
First-in-man / proof of concept study with molidustat - a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity.
HIF prolyl hydroxylase inhibitors for anemia.
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa.
Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.
Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Novel Iron Parameters in Patients with Type 2 Diabetes Mellitus in Relation to Kidney Function.
Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis associated with Acute Kidney Injury.
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease.
Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia.
Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia.
Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis.
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.
Treatment of anemia in difficult-to-manage patients with chronic kidney disease.
Treatment of Renal Anemia with Roxadustat: Advantages and Achievement.
[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
Aneurysm
Circulating tetrahydrobiopterin as a novel biomarker for abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Recoupling of eNOS with folic acid prevents abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E null mice.
Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid.
Suppression of abdominal aortic aneurysm formation by inhibition of prolyl hydroxylase domain protein through attenuation of inflammation and extracellular matrix disruption.
Atherosclerosis
Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia.
Autoimmune Diseases
American chemical society - 239th national meeting - investigating new therapeutic candidates: part 2.
Bone Resorption
Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2.
Brain Injuries
Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia.
Breast Neoplasms
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Detection of a 4-bp Insertion/deletion Polymorphism within the Promoter of EGLN2 Using Mismatch PCR-RFLP and Its Association with Susceptibility to Breast Cancer
DNA methylation analysis of the HIF-1? prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas.
EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer.
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
EglN2 positively regulates mitochondrial function in breast cancer.
Hypoxia represses microRNA biogenesis proteins in breast cancer cells.
Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer.
Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-?1 processing.
Long non-coding RNA LINC00662 promotes proliferation and migration of breast cancer cells via regulating the miR-497-5p/EglN2 axis.
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine.
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.
Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.
Carcinogenesis
Association of chromosome 19 to lung cancer genotypes and phenotypes.
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer.
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
EglN2 positively regulates mitochondrial function in breast cancer.
Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer.
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.
Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells.
Carcinoma
Activation of prolyl hydroxylase-2 for stabilization of mitochondrial stress along with simultaneous downregulation of HIF-1?/FASN in ER + breast cancer subtype.
An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk.
Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma.
Effect of Voacamine upon inhibition of hypoxia induced fatty acid synthesis in a rat model of methyln-nitrosourea induced mammary gland carcinoma.
Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand.
Carcinoma, Hepatocellular
Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo.
Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer.
Carcinoma, Renal Cell
Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma.
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells.
Carcinoma, Squamous Cell
Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Choroidal Neovascularization
Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization.
Chronic Limb-Threatening Ischemia
HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cells-based therapies for the treatment of critical limb ischemia.
Colitis
Hypoxia and gastrointestinal disease.
Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function.
N-(2-Mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: implication in amelioration of rat colitis by the antioxidant.
Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis.
Colorectal Neoplasms
An insertion/deletion polymorphism within the promoter of EGLN2 is associated with susceptibility to colorectal cancer.
Dystonia
Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice.
Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse.
GCH1 variants, tetrahydrobiopterin and their effects on pain sensitivity.
Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse.
Endometrial Neoplasms
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Escherichia coli Infections
Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1?.
Gastroparesis
In vivo ultrasound assessment of gastric emptying in newborn mice.
Glioblastoma
Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-?.
Glioma
Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD.
Glucose Intolerance
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
gtp cyclohydrolase i deficiency
GTP cyclohydrolase I expression, protein, and activity determine intracellular tetrahydrobiopterin levels, independent of GTP cyclohydrolase feedback regulatory protein expression.
Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse.
Heart Defects, Congenital
An EGLN1 mutation may regulate hypoxic response in cyanotic congenital heart disease through the PHD2/HIF-1A pathway.
Herpes Simplex
Antiviral activities against herpes simplex virus type 1 by HPH derivatives and their structure-activity relationships.
Hyperemia
GTP-cyclohydrolase deficiency induced peripheral and deep microcirculation dysfunction with age.
Hyperglycemia
Elevating VEGF-A and PDGF-BB secretion by salidroside enhances neoangiogenesis in diabetic hind-limb ischemia.
ROS- and HIF1?-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis.
Hypersensitivity
Erythrocytosis: genes and pathways involved in disease development.
Hypertension
GTP cyclohydrolase I/BH4 pathway protects EPCs via suppressing oxidative stress and thrombospondin-1 in salt-sensitive hypertension.
Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse.
Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid.
[Correlation between EGLN1 gene, protein express in lung tissue of rats and pulmonary artery pressure at different altitude].
Hypertension, Pulmonary
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension.
Prolyl Hydroxylase Domain-2 Protein Regulates Lipopolysaccharide-Induced Vascular Inflammation.
Pulmonary hypertension in the newborn GTP cyclohydrolase I-deficient mouse.
hypoxia-inducible factor-proline dioxygenase deficiency
Neuronal prolyl-4-hydroxylase 2 deficiency improves cognitive abilities in a murine model of cerebral hypoperfusion.
Tetrahydrobiopterin (BH
Infections
Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1?.
Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models.
Insulin Resistance
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
Intellectual Disability
Transmembrane Prolyl 4-Hydroxylase is a Novel Regulator of Calcium Signaling in Astrocytes.
Ischemic Attack, Transient
Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia.
Ischemic Stroke
HIF-prolyl hydroxylase 2 silencing using siRNA delivered by MRI-visible nanoparticles improves therapy efficacy of transplanted EPCs for ischemic stroke.
Neuronal deficiency of HIF prolyl 4-hydroxylase 2 in mice improves ischemic stroke recovery in an HIF dependent manner.
Kidney Diseases
?-Ketoglutarate-related inhibitors of HIF prolyl hydroxylases are substrates of renal organic anion transporters 1 (OAT1) and 4 (OAT4).
A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
Inhibitors of oxygen sensing prolyl hydroxylases regulate nuclear localization of the transcription factors Smad2 and YAP/TAZ involved in CTGF synthesis.
Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
Liver Diseases
Regulatory Role of Endothelial PHD2 in the Hepatic Steatosis.
Liver Neoplasms
Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice.
Lung Neoplasms
Correlations of an Insertion/Deletion Polymorphism (rs10680577) in the RERT-lncRNA with the Susceptibility, Clinicopathological Features, and Prognosis of Lung Cancer.
Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer.
The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer.
The predictive prognostic values of CBFA2T3, STX3, DENR, EGLN1, FUT4, and PCDH7 in lung cancer.
Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.
Melanoma
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.
Mitochondrial Diseases
Biallelic P4HTM variants associated with HIDEA syndrome and mitochondrial respiratory chain complex I deficiency.
Monoclonal Gammopathy of Undetermined Significance
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Mouth Neoplasms
Hypoxia responsiveness linked variant in EGLN1 gene is enriched in oral cancer patients.
Multiple Myeloma
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Myocardial Infarction
Targeted Gene deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis And Preserves Cardiac Function by stabilizing Hypoxia inducible Factor 1 Alpha Following Myocardial Infarction.
Nasopharyngeal Neoplasms
Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene.
Neoplasm Metastasis
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.
Hypoxia-inducible factors as key regulators of tumor inflammation.
Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer.
Thermal unfolding pathway of PHD2 catalytic domain in three different PHD2 species: computational approaches.
Neoplasms
A New Role for PHD in Chemotherapy.
Activation of prolyl hydroxylase-2 for stabilization of mitochondrial stress along with simultaneous downregulation of HIF-1?/FASN in ER + breast cancer subtype.
An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk.
Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation.
Association between an indel polymorphism within the distal promoter of EGLN2 and cancer risk: An updated meta-analysis.
Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer.
Clockophagy is a novel selective autophagy process favoring ferroptosis.
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Correlations of an Insertion/Deletion Polymorphism (rs10680577) in the RERT-lncRNA with the Susceptibility, Clinicopathological Features, and Prognosis of Lung Cancer.
Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma.
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice.
Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo.
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.
Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Estrogen receptor ? sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription.
Exposure to cigarette smoke induces overexpression of von Hippel-Lindau tumor suppressor in mouse skeletal muscle.
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.
Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk.
Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.
HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGF? activation.
HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression.
Hypoxia Exacerbates Inflammatory Acute Lung Injury via the Toll-Like Receptor 4 Signaling Pathway.
Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
Hypoxia-inducible factors as key regulators of tumor inflammation.
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
Identification of hub genes and key pathways associated with the progression of gynecological cancer.
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Induction of plasminogen activator inhibitor I gene expression by intracellular calcium via hypoxia-inducible factor-1.
Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Anti-Proliferative Activity of Transforming Growth Factor{beta}
Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression.
Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-?1 processing.
Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors.
Paragangliomas/Pheochromocytomas: clinically oriented genetic testing.
PHD2 mutation and congenital erythrocytosis with paraganglioma.
Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer.
Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism.
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism.
Prolyl hydroxylase-2 inhibits liver tumor cell proliferation and cyclin D1 expression in a hydroxylase-dependent manner.
Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma.
Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4.
Regulation of IL-1?-induced NF-?B by hydroxylases links key hypoxic and inflammatory signaling pathways.
Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.
The non-canonical functions of HIF prolyl hydroxylases and their dual roles in cancer.
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
The role of HIF prolyl hydroxylases in tumor growth.
The roles and signaling pathways of prolyl-4-hydroxylase 2 in the tumor microenvironment.
The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Neuroblastoma
An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha.
Neurofibromatoses
Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches.
Non-alcoholic Fatty Liver Disease
Regulatory Role of Endothelial PHD2 in the Hepatic Steatosis.
Obesity
HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction.
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
Ovarian Neoplasms
Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.
Pancreatic Neoplasms
Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer.
Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1?.
Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer.
Paraganglioma
Modeling dioxygenase enzyme kinetics in familial paraganglioma.
Paraganglioma, Extra-Adrenal
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
Paraproteinemias
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Parkinson Disease
A protective role for N-acylphosphatidylethanolamine phospholipase D in 6-OHDA-induced neurodegeneration.
Genetic Analysis of EGLN1 C127S Variant in Taiwanese Parkinson's Disease.
Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson's Disease.
Regulation of ATP13A2 via PHD2-HIF1? Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.
Peripheral Arterial Disease
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease.
Phenylketonurias
A histological study of the hph-1 mouse mutant: an animal model of phenylketonuria and infantile hypertrophic pyloric stenosis.
Anxiety- and depression-like phenotype of hph-1 mice deficient in tetrahydrobiopterin.
Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse.
Impairment of the nitric oxide/cyclic GMP pathway in cerebellar slices prepared from the hph-1 mouse.
Molecular characterization of HPH-1: a mouse mutant deficient in GTP cyclohydrolase I activity.
Neurochemical effects following peripheral administration of tetrahydropterin derivatives to the hph-1 mouse.
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension.
Regulation of ?-adrenergic control of heart rate by GTP-cyclohydrolase 1 (GCH1) and tetrahydrobiopterin.
Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease.
Tetrahydrobiopterin (BH4) deficiency is associated with augmented inflammation and microvascular degeneration in the retina.
Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism.
Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse.
Tetrahydrobiopterin availability, nitric oxide metabolism and glutathione status in the hph-1 mouse; implications for the pathogenesis and treatment of tetrahydrobiopterin deficiency states.
Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse.
Pneumonia
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: implication in manganese-induced pulmonary inflammation.
Manganese (II) induces chemical hypoxia by inhibiting HIF-prolyl hydroxylase: Implication in manganese-induced pulmonary inflammation.
Polycythemia
An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23.
Congenital erythrocytosis - discover of a new mutation in the EGLN1 gene.
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
EPAS1 p.M535T mutation in a Bulgarian family with congenital erythrocytosis.
Erythrocytosis: genes and pathways involved in disease development.
Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience.
Hereditary gene mutations in Korean patients with isolated erythrocytosis.
Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
Identification of Variants Associated With Rare Hematological Disorder Erythrocytosis Using Targeted Next-Generation Sequencing Analysis.
Isolated Erythrocytosis Associated With 3 Novel Missense Mutations in the EGLN1 Gene.
Loss-of-function zinc finger mutation in the EGLN1 gene associated with erythrocytosis.
Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).
Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.
PHD2 mutation and congenital erythrocytosis with paraganglioma.
Prolyl-4-Hydroxylase 2 Potentially Contributes to Hepatocellular Carcinoma-Associated Erythrocytosis by Maintaining Hepatocyte Nuclear Factor-4? Expression.
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
The Zinc Finger of Prolyl Hydroxylase Domain Protein 2 Is Essential for Efficient Hydroxylation of Hypoxia-Inducible Factor ?.
[A new case of rare erythrocytosis due to EGLN1 mutation with review of the literature].
Pre-Eclampsia
High altitude and pre-eclampsia: Adaptation or protection.
Novel association of SNP rs479200 in EGLN1 gene with predisposition to preeclampsia.
Prostatic Neoplasms
Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer.
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Pulmonary Arterial Hypertension
[Correlation between EGLN1 gene, protein express in lung tissue of rats and pulmonary artery pressure at different altitude].
Pulmonary Disease, Chronic Obstructive
EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population.
Refining susceptibility loci of chronic obstructive pulmonary disease with lung eqtls.
Smoking dysregulates the human airway basal cell transcriptome at COPD risk locus 19q13.2.
Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.
Pulmonary Edema
EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda.
Raised HIF1? during normoxia in high altitude pulmonary edema susceptible non-mountaineers.
Pyloric Stenosis, Hypertrophic
A histological study of the hph-1 mouse mutant: an animal model of phenylketonuria and infantile hypertrophic pyloric stenosis.
Infantile hypertrophic pyloric stenosis (IHPS): a study of its pathophysiology utilizing the newborn hph-1 mouse model of the disease.
Renal Insufficiency
HIF prolyl hydroxylase inhibitors for anemia.
Renal Insufficiency, Chronic
HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity.
Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.
[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
Reperfusion Injury
HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity.
Sarcoma
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Spinal Cord Injuries
Hypoxia-inducible factor prolyl hydroxylase domain (PHD) inhibition after contusive spinal cord injury does not improve locomotor recovery.
Stomach Neoplasms
An Insertion/Deletion Polymorphism Within the Proximal Promoter of EGLN2 Is Associated With Susceptibility for Gastric Cancer in the Chinese Population.
Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer.
Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer.
Stroke
HIF prolyl hydroxylase inhibitors for anemia.
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.
Thrombosis
Hypoxia and Upregulation of Hypoxia-Inducible Factor 1{alpha} Stimulate Venous Thrombus Recanalization.
Inhibition of prolyl hydroxylase domain proteins selectively enhances venous thrombus neovascularisation.
Triple Negative Breast Neoplasms
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.
Uterine Neoplasms
Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1.
Vascular System Injuries
Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury.
Ventricular Dysfunction
Chronic Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl 4-Hydroxylase Improves Ventricular Performance, Remodeling and Vascularity Following Myocardial Infarction in the Rat.